Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Lovisa Odén1,2, Mohammad Akbari1,3, Tasnim Zaman1,5, Christian F. Singer4, Ping Sun1, Steven A. Narod1,3, Leonardo Salmena5,6, Joanne Kotsopoulos1,3

1Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada, M5S 1B2
2Karolinska Institutet, SE-171 77, Stockholm, Sweden
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, M5T 3M7
4Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Spitalgasse 23, 1090 Wien, Vienna, Austria
5Department of Pharmacology and Toxicology, University of Toronto, 1 King’s College Circle Toronto, ON, Canada, M5S 1A8
6Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, M5G 2M9

Correspondence to: Joanne Kotsopoulos, email: joanne.kotsopoulos@wchospital.ca

Keywords: osteoprotegerin (OPG), BRCA1/2, chemoprevention, breast cancer, receptor activator of nuclear factor κB (RANKL)

Received: September 02, 2016  Accepted: November 09, 2016  Published: November 22, 2016

ABSTRACT

Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA mutation carriers. Whether low OPG levels contribute to the high breast cancer risk in this population is unknown. OPG concentrations were measured in plasma of 206 cancer-free BRCA mutation carriers using an enzyme-linked immunosorbent assay. Subjects were categorized as high vs. low based on the median of the entire cohort (95 ng/mL) and followed for a new diagnosis of breast cancer. Cumulative incidence by baseline plasma OPG concentration was estimated using Kaplan-Meier survival analysis. Cox proportional hazards models were used to estimate the adjusted hazard ratios for the association between plasma OPG and breast cancer risk. Over a mean follow-up period of 6.5 years (range 0.1–18.8 years), 18 incident breast cancer cases were observed. After ten years of follow-up, the cumulative incidence of breast cancer among women with low OPG was 21%, compared to 9% among women with high OPG (P-log rank = 0.046). After multivariate adjustment, women with high plasma OPG had a significantly decreased risk of developing breast cancer, compared to women with low OPG (HR = 0.25; 95%CI 0.08–0.78; P = 0.02). These data suggest that low OPG levels are associated with an increased risk of BRCA-associated breast cancer. Targeting RANK signalling may represent a plausible, non-surgical prevention option for BRCA mutation carriers.

INTRODUCTION

Women who inherit a deleterious mutation in one of the two breast cancer susceptibility genes, BRCA1 or BRCA2, face a high lifetime risk of breast cancer, compared to women in the general population [1–3]. Genetic testing for mutations in BRCA1 or BRCA2 identifies women at a high-risk of developing breast cancer; however, to date the only highly effective primary breast cancer prevention strategy is prophylactic bilateral mastectomy [4–6]. Furthering our understanding of the underlying biology of BRCA-associated cancer development should translate into targeted chemoprevention options for this high-risk population.

Evidence from both epidemiologic and experimental studies point towards an important role of progesterone-
signaling in breast cancer development. Findings from the Women’s Health Initiative (WHI), a randomized placebo-controlled trial of hormone replacement therapy showed that combined therapy (i.e., estrogen plus progesterone) was associated with a significant increased risk of breast cancer (hazard ratio [HR] = 1.55; 95%CI 1.41–1.70) [7] whereas the use of estrogen alone was associated with a decreased risk (HR = 0.77; 95%CI 0.62–0.95) [8]. In vivo studies have provided mechanistic evidence to explain these observations. Various groups have demonstrated that progesterone-mediated up-regulation of the receptor activator of nuclear factor κB signaling pathway (RANK)/RANK ligand (RANKL) plays a critical role in mammary gland epithelial cell proliferation, in mammary stem cell expansion, and in carcinogenesis [9–13]. Recently, two independent reports showed that inhibition of RANKL significantly suppressed mammary tumorigenesis in Brca1 deficient mice [14, 15]. Moreover, Widschwendter et al. reported significantly lower mean circulating levels of osteoprotegerin (OPG), the endogenous decoy receptor for RANKL that antagonizes RANK/RANKL-mediated signaling, as well as higher progesterone levels among premenopausal BRCA mutation carriers compared to non-carrier controls [16, 17]. Together, these studies strongly suggest that a role for the progesterone-mediated RANK/RANKL signaling pathway in the development of mammary carcinogenesis may be particularly relevant in women with a BRCA mutation. Therefore, targeting aberrancies in RANKL signaling may represent a plausible, non-surgical chemoprevention option for this high-risk population.

Despite the emerging importance of RANK signaling in breast cancer, no studies have directly measured the association between circulating OPG levels and subsequent breast cancer risk. Thus, we undertook a prospective analysis of plasma OPG levels and breast cancer risk in 206 women with a BRCA1 or BRCA2 mutation that were unaffected by breast cancer at the time of study enrollment.

RESULTS

There were 206 women with a BRCA1 or BRCA2 mutation included in the current study. The baseline characteristics of the women are summarized in Table 1. The median baseline OPG level was 65.2 pg/ml (interquartile range [IQR] 46.7 to 83.3 pg/ml) among women in the low group and 134.9 pg/ml (IQR 112.2 to 191.9 pg/ml) among those in the high group. Women with low plasma OPG levels were younger, on average compared to women with high OPG levels (P = 0.008). Other baseline characteristics, including reproductive factors, body mass index, and menopausal status, were similar between the two groups.

Over a mean follow-up period of 6.5 years (range 0.1–18.8 years), 18 incident cases of primary invasive breast cancer were observed in the cohort. Thirteen (13%) of the women with low OPG developed breast cancer compared to 6 (6%) of the women with high OPG levels (P = 0.09). Women who developed breast cancer had significantly lower mean baseline OPG concentrations (90.59 pg/ml [range 4.2–205.7 pg/ml]) compared to the OPG concentrations of women who did not develop breast cancer (117.9 pg/ml [7.4–547.7]) (P = 0.04). BRCA mutation carriers with low baseline OPG concentrations (< 95 pg/ml) had a significantly higher risk of developing breast cancer compared to those with high baseline OPG concentrations (> 95 pg/ml)(Figure 1). After ten years of follow-up, the cumulative incidence of breast cancer among women with low OPG concentrations was 21% (95%CI 12%–35%) compared to 9% (95%CI 4%–21%) among women with high OPG concentrations (P-log rank test = 0.046).

Table 2 summarizes the hazard ratio (HR) and associated 95% confidence intervals (CI) of breast cancer associated with plasma OPG levels among BRCA1 and BRCA2 mutation carriers. After adjusting for age at blood draw, women with high plasma OPG levels had a significantly decreased risk of developing breast cancer compared to women with low plasma OPG levels (HR = 0.30; 95% CI 0.10–0.86; P = 0.02). Results were similar in the multivariate analysis adjusting for potential confounders including BRCA mutation type, oophorectomy, breastfeeding and oral contraceptive use (HR = 0.25; 95% CI 0.08–0.78; P = 0.02)(Table 2). In the analysis stratified by BRCA mutation, the adjusted estimates were 0.39 (95% CI 0.08–1.85; P = 0.24) for BRCA1 and 0.10 (95% CI 0.01–0.95; P = 0.04) for BRCA2 mutation carriers (data not shown).

DISCUSSION

In this study, we demonstrate a significant inverse relationship between plasma OPG levels and breast cancer risk among 206 women with an inherited BRCA1 or BRCA2 mutation. Women with low OPG levels were more likely to develop breast cancer compared to women with high levels. These findings are timely given the emerging importance of RANK/RANKL-signaling in mammary tumour development, which may be of more relevance for BRCA mutation carriers [14, 15]. Normally, OPG regulates RANK/RANKL-signaling by binding to RANKL as a decoy receptor and thereby inhibiting signal transduction [18]. Recent studies have described progesterone-mediated RANKL signaling on ER/PR-negative epithelial stem and progenitor cell populations as a mechanism contributing to mammary tumorigenesis [19, 20]; however, the direct role of OPG on risk of developing BRCA-breast cancer has not been evaluated. Our data adds to a rapidly emerging body of evidence that a BRCA mutation may be associated with aberrancies in the OPG/RANK- signaling axis and may represent a potential therapeutic target for the non-surgical prevention of breast cancer in this high-risk population.
Our results extend the findings of Widschwendter et al., who demonstrated lower serum OPG levels among BRCA mutation carriers (n = 391) compared to non-carriers (n = 782) across the menstrual cycle (P = 0.06) [17]. They also reported that progesterone levels were higher during day 6 to day 24 (i.e., luteal phase) of the menstrual cycle of BRCA mutation carriers (particularly BRCA1 mutation carriers) vs. non-carriers. Of importance was a significant inverse relationship between luteal progesterone and OPG among women with a mutation (ρ = −0.216; P = 0.002) vs. those without (ρ = −0.098; P = 0.06). Using female cynomolgus macaques, the authors showed that treatment with estrogen plus progesterone (but not estrogen alone or no hormones) was associated with significantly lower mammary tissue and serum OPG levels. Importantly, there was a significant

| Table 1: Characteristics of BRCA mutation carriers by plasma osteoprotegerin (OPG) levels |
|---------------------------------|---------------------------------|---------------------------------|
| Variable                        | Low OPG (n = 103)               | High OPG (n = 103)               | P§      |
|---------------------------------|---------------------------------|---------------------------------|---------|
| Osteoprotegerin (ng/ml), mean (range) | 62.9 (4.2–94.5)               | 168.1 (95.5–547.7)               | < 0.0001|
| Year of birth, mean (range)     | 1965.0 (1931.4–1990.5)          | 1959.8 (1911.7–1990.5)           | 0.008   |
| Age at blood draw, mean (range), years | 40.8 (19.6–70.6)               | 44.2 (17.6–84.7)                 | 0.06    |
| Mean follow-up, years (range)   | 6.3 (0.2–17.7)                 | 6.6 (0.1–18.8)                  | 0.69    |
| BRCA mutation                   |                                |                                |         |
| BRCA1                           | 59 (57.3)                      | 61 (59.2)                       |         |
| BRCA2                           | 44 (42.7)                      | 41 (39.8)                       |         |
| BRCA1 and BRCA2                 | 0                              | 1 (1.0)                        | 0.57    |
| Oophorectomy, n (%)             | 59 (57.3)                      | 62 (60.9)                       | 0.67    |
| Breast cancer, n (%)            |                                |                                |         |
| No                              | 90 (87.4)                      | 97 (94.2)                       |         |
| Yes                             | 13 (12.6)                      | 6 (5.8)                         | 0.09    |
| Age at diagnosis, mean (range)  | 51.4 (33.9–62.7)               | 49.1 (35.5–72.4)                | 0.67    |
| Parity, n (%)                   |                                |                                |         |
| Nulliparous                     | 33 (32.7)                      | 31 (30.1)                       |         |
| 1                               | 9 (8.9)                        | 8 (7.8)                         |         |
| 2                               | 37 (36.6)                      | 34 (33.0)                       |         |
| 3                               | 17 (16.8)                      | 16 (15.5)                       |         |
| ≥ 4                             | 5 (5.0)                        | 14 (13.6)                       | 0.34    |
| Mean (range)                    | 1.5 (0–5)                      | 1.8 (0–7)                       | 0.15    |
| Missing                         | 2                              | 0                               |         |
| Breastfeeding, n (%)            |                                |                                |         |
| Never                           | 50 (49.5)                      | 44 (43.1)                       |         |
| Ever, < 12 months               | 26 (25.7)                      | 26 (25.5)                       |         |
| Ever, ≥ 12 months               | 25 (24.8)                      | 32 (31.4)                       | 0.53    |
| Mean (range), months            | 8.5 (0–126)                    | 9.6 (0–86)                      | 0.63    |
| Missing                         | 2                              | 1                               |         |
| Oral contraceptive use, n (%)   |                                |                                |         |
| Never                           | 26 (25.2)                      | 20 (19.4)                       |         |
| Ever                             | 76 (73.8)                      | 83 (80.6)                       |         |
| Missing                         | 1 (1.0)                        | 0                               | 0.35    |
| Body mass index, mean (range)   | 25.2 (17.2–45.3)               | 24.6 (17.9–45.1)                | 0.37    |
| Tamoxifen use, n (%)             |                                |                                |         |
| Never                           | 102 (99.0)                     | 102 (99.0)                      |         |
| Ever                             | 1 (1.0)                        | 1 (1.0)                         | 1.00    |
| Menopausal status, n (%)         |                                |                                |         |
| Premenopausal                   | 77 (74.8)                      | 64 (62.1)                       |         |
| Postmenopausal                  | 26 (25.2)                      | 39 (37.9)                       | 0.05    |

*Oophorectomy refers to bilateral oophorectomy.

§P values were calculated using the Student’s t-test for continuous variables and the chi-square test for categorical variables. Missing data were not included in the analysis. All tests are two-sided.
Table 2: Hazard ratio (HR) and 95% confidence interval (CI) of breast cancer by plasma osteoprotegerin (OPG) levels

| Variable                        | Age-adjusted* HR (95% CI) | P-value | Multivariate§ HR (95% CI) | P-value |
|---------------------------------|---------------------------|---------|---------------------------|---------|
| Plasma osteoprotegerin (OPG)   |                            |         |                           |         |
| Low                             | 1.00 (reference)          | 0.02    | 1.00 (reference)          | 0.02    |
| High                            | 0.30 (0.10–0.86)          | 0.04    | 0.25 (0.08–0.78)          | 0.02    |
| Age at blood draw (continuous)  | 1.04 (1.00–1.08)          | 0.04    | 1.05 (1.01–1.10)          | 0.02    |
| BRCA mutation type              |                            |         |                           |         |
| BRCA1                           | 1.00 (reference)          | 0.80    | 1.00 (reference)          | 0.89    |
| BRCA2                           | 1.11 (0.44–2.80)          | 0.14    | 0.93 (0.35–2.51)          | 0.89    |
| Oophorectomy                    |                            |         |                           |         |
| No                              | 1.00 (reference)          | 0.14    | 0.49 (0.19–1.27)          | 0.06    |
| Yes                             | 0.49 (0.19–1.27)          | 0.14    | 0.34 (0.11–1.04)          | 0.06    |
| Breastfeeding                   |                            |         |                           |         |
| Never                           | 1.00 (reference)          | 0.46    | 1.00 (reference)          | 0.28    |
| < 1 year                        | 1.50 (0.51–4.43)          | 0.76    | 1.89 (0.60–5.97)          | 0.96    |
| ≥ 1 year                        | 0.81 (0.24–2.71)          | 0.76    | 1.03 (0.30–3.57)          | 0.76    |
| Oral contraceptive use         |                            |         |                           |         |
| Never                           | 1.00 (reference)          | 0.82    | 1.00 (reference)          | 0.27    |
| Ever                            | 1.15 (0.35–3.73)          | 0.82    | 2.17 (0.55–8.54)          | 0.27    |

*Adjusted for age at blood draw.

§Adjusted for age at blood draw as well as other variables in the model (BRCA mutation, oophorectomy, breastfeeding and oral contraceptive use).

Figure 1: Incidence of breast cancer among BRCA1 and BRCA2 mutation carriers with high (>95 ng/ml) vs. low (≤95 ng/ml) plasma OPG levels.
inverse correlation between serum OPG levels and mammary gland proliferation as per Ki67 expression analysis (rho = -0.545; P < 0.001). Although estrogen plus progesterone was also associated with an upregulation of RANKL in the mammary tissue, this was not reflected in the serum. These findings suggest a local effect of progesterone that could explain the tissue-specificity of cancer development in response to aberrant OPG/RANKL levels.

To our knowledge, our study represents the first investigation of plasma OPG levels and breast cancer risk in BRCA mutation carriers. Our study is consistent with a recent and only evaluation of serum OPG levels and subsequent cancer risk in non-carriers. Among 6,279 subjects from the general population in Norway with a median follow-up of 13.5 years (3,174 women), Vik et al., reported a significant inverse relationship between serum OPG levels and breast cancer risk (HR tertile 3 vs. tertile 1 = 0.24; 95%CI 0.10–0.61; P – trend = 0.002) [21]. Although the expected number of mutation carriers is likely very small in this study, it is of interest that the protective effect of high circulating OPG was only seen in premenopausal women, given that BRCA1 mutation carriers typically present disease at a young age (< 50 years) [22]. In our study, the average age at diagnosis was 50.7 and 37% were diagnosed prior to age 50.

Evidence from experimental studies strongly support a role of progesterone-mediated RANKL signaling in the development of BRCA-associated breast cancer. In vivo studies have demonstrated that progesterone is directly (via binding to the progesterone receptor [PR]) and indirectly (via RANKL) involved in normal mammary gland development as well as mammary tumorigenesis [10, 11, 23]. Specifically, binding of RANKL to RANK in response to progesterone stimulates mammary epithelial cells maturation and proliferation. Inhibition of either RANKL or progesterone by pharmacological agents or inactivation of RANK are associated with a reduction in mammary carcinogenesis [10, 11, 23]. Conversely, overexpressing RANK enhances mammary tumor formation in the presence of progesterone [11] while in vivo administration of a synthetic progesterone upregulates RANKL levels in mammary epithelial cells [10]. Poole et al., demonstrated that treatment of brca1/p53-deficient mice with the progesterone antagonist mifepristone prevented mammary tumorigenesis [23]. Epidemiologic evidence also supports a harmful role of progesterone, given that only combined hormone replacement therapy (i.e., estrogen plus progesterone) has been associated with an increased risk of developing breast cancer [24].

Of particular importance are studies demonstrating that progesterone-driven RANKL-signalling is implicated in the regulation and expansion of mammary stem and progenitor cells [11–13]. Joshi and colleagues have showed progesterone-mediated expansion of the luminal progenitor cells in human breast tissue which is of direct relevance for BRCA1 mutation carriers who have an increased propensity to develop breast tumours with stem cell-like properties [25]. Specifically, emerging evidence points to the luminal progenitor population as the cell of origin of BRCA1-associated breast tumours [26]. Accordingly, Lim et al., showed that breast cells isolated from BRCA1 mutation carriers exhibit an expanded luminal progenitor subpopulation compared to normal mammary tissue [26]. In a recent publication, Nolan et al., demonstrated that RANK expression was highest in the luminal progenitor cells (normal breast and tumour tissue) of BRCA1 mutation carriers compared to tissue from both wild-type and BRCA2 mutation carriers [14]. They also showed a decrease in breast epithelial cell proliferation in three premenopausal women treated with denosumab, and a significant increase in basal-like tumor latency in mammary hyperplasia among Brca1 deficient mice (that also develop) treated with a RANKL inhibitor (15). Importantly, these findings were validated in a concomitant study led by Sigl and colleagues [15].

The annual risk for breast cancer in BRCA4 mutation carriers is ~2% between the ages of 30 and 60. Ideally, a drug intervention would need to occur early in adulthood and have no serious or long-term side effects. Quantifying OPG levels could help stratify women who are at a higher risk of developing disease who may be targets for alternative chemoprevention options. The low endogenous levels of OPG coupled with the significant lifetime risks of breast and ovarian cancer in BRCA4 mutation carriers, strongly support the use of an anti-RANKL monoclonal antibody like denosumab for the prevention of hereditary breast cancer while simultaneously maintaining bone density. Last year, authors of the adjuvant denosumab (a monoclonal antibody that binds RANKL) in breast cancer trial (ABCGS-18) published no additional toxicity and a favorable safety profile of adjuvant denosumab therapy (60 mg subcutaneously biannually) among women with early breast cancer treated with aromatase inhibitors compared to the placebo group [27]. Furthermore, a recent follow-up analysis of the trial showed improved disease-free survival among the women receiving adjuvant denosumab [28]. An effect on the incidence of a second primary cancer will be of interest.

Our study has several limitations. The sample size was small, the number of incident cases was low and the finding was of marginal statistical significance. We were not sufficiently powered to conduct robust analyses subdivided by BRCA4 mutation type. Although we did not have data on timing of blood collection, Widenschwendter et al. clearly showed no variation of OPG within the menstrual cycle and there was no difference in OPG levels by menopausal status in our cohort of BRCA4 mutation carriers (data not shown). We did not evaluate levels of RANKL in our analysis. Despite this, the recent findings from Nolan and colleagues of increased RANK in BRCA1 luminal progenitors suggests that it may be of interest to
evaluate circulating RANKL levels in future studies with a much larger number of women.

Notwithstanding these limitations, this is the first report of circulating OPG and breast cancer risk among women with a BRCA mutation. Pending validation in a larger study, the integration of OPG levels may help identify those women who may benefit from treatment with RANKL blockade to prevent breast cancer. Inhibiting RANK-signaling by an existing monoclonal antibody (i.e., denosumab) to simultaneously prevent breast cancer and maintain bone health (particularly after salpingo-oophorectomy) represents an important opportunity that warrants exploration in a primary prevention trial of BRCA mutation carriers.

MATERIALS AND METHODS

Study population

We identified potentially eligible women from a longitudinal study of BRCA1 and BRCA2 mutation carriers [29]. For the current prospective cohort study, we included women from Ontario, Canada, who had received genetic counselling at the Familial Breast Cancer Research Unit, Women’s College Hospital (Toronto, Canada). These women sought testing for BRCA1 or BRCA2 mutations because of a personal or family history of breast and/or ovarian cancer. Mutation detection was conducted using a range of techniques, but all nucleotide sequences were confirmed by direct sequencing of DNA. The study was approved by the institutional ethics review boards of the host institutions and all study subjects provided written informed consent.

Data and sample collection

All study subjects completed a baseline questionnaire at the time of study enrolment. These were either mailed to each study participant or administered over the phone by a genetic counsellor or research assistant at the time of genetic testing and collected information regarding family history, reproductive and medical histories, preventive oophorectomy and mastectomy, and select lifestyle factors such as alcohol and coffee consumption. Follow-up questionnaires were completed every two years thereafter to update information on relevant reproductive, medical and lifestyle information, and to ascertain incident cancers.

Blood samples were collected at the time of genetic testing and baseline questionnaire administration into EDTA- or citrate-containing tubes by venipuncture, processed and separated into plasma and DNA and stored at −80°C and 4°C respectively, at the Women’s College Hospital.

Study subjects available for analysis

Women were eligible for inclusion in the current study if they were between the ages of 18–70 years at the time of enrolment and completed at least one follow-up questionnaire. Of the 751 women who were initially eligible, we excluded those who had a previous history of breast or ovarian cancer (n = 284), those who had previously undergone a prophylactic bilateral mastectomy (n = 11), and those who did not have a baseline plasma sample available (n = 250). After these exclusions, a total of 206 participants were available for the plasma OPG analysis.

OPG ELISA

Plasma OPG was quantified using a commercial ELISA kit from ALPCO (Salem, NH – catalogue #04-BI-20403) according to the manufacturer’s protocol. Briefly, all patient plasma samples were run in duplicate. The concentration of OPG was calculated as the average of duplicate samples (each adjusted for background signal and normalized to blank wells) and subsequently converted to a total OPG concentration upon comparison to OPG standards provided in the kit.

Statistical analysis

Plasma OPG was categorized as high or low based on the median distribution in the entire cohort (≤ 95 and > 95 ng/mL). The student’s t-test and χ² test were used to evaluate differences in the baseline characteristics of the women with high vs. low OPG levels.

Participants were followed from date of completion of the baseline questionnaire until either the date of their breast cancer diagnosis, date of prophylactic mastectomy, date of ovarian cancer diagnosis, date of death or date of completion of their last follow-up questionnaire. The follow-up period of this analysis was from the date of baseline questionnaire until June 26th, 2016.

We used the Kaplan-Meier survival analysis to estimate the cumulative incidence of breast cancer in women with high vs. low plasma OPG levels. Incidence rates in the two groups were compared using a log-rank test. We employed Cox proportional hazards models to estimate the hazard ratio (HR) and 95% confidence interval (CI) associated with plasma OPG levels. The multivariable model was adjusted for age at blood draw (continuous), BRCA mutation type (BRCA1 or BRCA2), oophorectomy (yes/no), breastfeeding (never, < 1 year, ≥ 1 year) and oral contraceptive use (never, ever). All analyses were conducted using SAS version 9.4 software (SAS Institute, Cary, NC). All P values were 2-sided and were considered statistically significant if P ≤ 0.05.

Authors’ contributions

JK conceived and designed the study, obtained funding, and was involved in data analysis and manuscript preparation. LO and LS were responsible for conducting the ELISAs, statistical analysis and manuscript preparation.
preparation. SAN was involved in acquisition of samples, data analysis and manuscript preparation. CFS, MA and TZ were involved in manuscript preparation. PS was involved in data analysis.

ACKNOWLEDGMENTS

We would like to acknowledge the study coordinators Marcia Llacuachaqui, Farah Shoukat, and Alejandra Ragone, as well as the students and staff Ellen MacDougall, Zoella Pasta, Nida Mian, Jennifer Ng, Sarah Chin, Hamida Begum, Harmee Chaudhary, and Yaminee Charavanapavan who helped with the data collection and data entry.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

JK is the recipient of a Cancer Care Ontario Research Chair in Population Studies and a Canadian Cancer Society Career Development Award in Prevention. SAN is the recipient of a Tier I Canada Research Chair. LS is the recipient of a Tier II Canada Research Chair.

REFERENCES

1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25:1329–1333.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343:692–695.
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72:1117–1130.
4. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345:159–164.
5. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93:1633–1637.
6. Rebbeck TR, Friebl T, Lynch HT, Neuhausen SL, van ’t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22:1055–1062.
7. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Waetawski-Wendt J, Chen C, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst. 2013; 105:526–535.
8. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012; 13:476–486.
9. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000; 103:41–50.
10. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010; 468:98–102.
11. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010; 468:103–107.
12. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010; 465:798–802.
13. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stigil J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature. 2010; 465:803–807.
14. Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, Kathleen Cunningham Foundation Consortium for Research into Familial Breast C, Rohrbach K, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 2016.
15. Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wimsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersh J, et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res. 2016; 26:761–774.
16. Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Internaggio MP, Edlund CK, Ramus SJ, Gayther SA, et al. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol. 2013; 14:1226–1232.
17. Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubau L, Cline M, Pan Y, Yi PC, et al. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-kappaB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. 2015; 2:1331–1339.

18. Nagy V, Penninger JM. The RANKL-RANK Story. Gerontology. 2015; 61:534–542.

19. Lee HJ, Gallego-Ortega D, Ledger A, Schramek D, Joshi P, Szwarc MM, Cho C, Lydon JP, Khokha R, Penninger JM, Ormandy CJ. Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development. 2013; 140:1397–1401.

20. Obr AE, Grimm SL, Bishop KA, Pike JW, Lydon JP, Edwards DP. Progesterone receptor and Stat5 signaling crosstalk through RANKL in mammary epithelial cells. Mol Endocrinol. 2013; 27:1808–1824.

21. Vik A, Brodin EE, Mathiesen EB, Brox J, Jorgensen L, Njolstad I, Braekkan SK, Hansen JB. Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromso study. Eur J Epidemiol. 2015; 30:219–230.

22. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izzat L, Eeles RA, Adlard J, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute. 2013; 105:812–822.

23. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006; 314:1467–1470.

24. Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O’Sullivan MJ, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015; 1:296–305.

25. Joshi PA, Waterhouse PD, Kannan N, Narala S, Fang H, Di Grappa MA, Jackson HW, Penninger JM, Eaves C, Khokha R. RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. Stem Cell Reports. 2015; 5:31–44.

26. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009; 15:907–913.

27. Gnant M, Pféifer G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386:433–443.

28. Gnant M PG, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, et al. on behalf of the Austrian Breast and Colorectal Cancer Study Group. The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. In San Antonio Breast Cancer Symposium2015: Abstract S2–02.

29. Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, et al. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast cancer research and treatment 2013, 142:177–185.